Skip to content
Call us :   +1.877.374.3207
wcclinical
  • Therapeutic Areas
    • ONCOLOGY
    • Ophthalmology
    • Cardiovascular
    • Musculoskeletal
    • Gastroenterology
    • Neurology
    • Hepatology (NASH/NAFLD)
  • Services
    • Imaging Services for Clinical Trials
    • Adjudication Committee Services
    • Trial Management
    • Central Reviews
    • DXA Services
  • About us
    • leadership
    • Science Team
    • Careers
    • News
  • Contact Us
Menu Close
  • Therapeutic Areas
    • ONCOLOGY
    • Ophthalmology
    • Cardiovascular
    • Musculoskeletal
    • Gastroenterology
    • Neurology
    • Hepatology (NASH/NAFLD)
  • Services
    • Imaging Services for Clinical Trials
    • Adjudication Committee Services
    • Trial Management
    • Central Reviews
    • DXA Services
  • About us
    • leadership
    • Science Team
    • Careers
    • News
  • Contact Us

Blog

Home » WORLDCARE CLINICAL PRESIDENT TO PRESENT AT CBI ENDPOINT ADJUDICATION CONFERENCE
You are currently viewing WORLDCARE CLINICAL PRESIDENT TO PRESENT AT CBI ENDPOINT ADJUDICATION CONFERENCE

WORLDCARE CLINICAL PRESIDENT TO PRESENT AT CBI ENDPOINT ADJUDICATION CONFERENCE

  • Post author:admin
  • Post published:May 1, 2015
  • Post category:Uncategorized

Boston, MA, May 1, 2015 — WorldCareClinical (WCC), one of the world’s leading imaging CROs focused on maximizing the precision and accuracy of independent endpoint assessments in clinical trials, today announced that WCC President Dr. Rick Walovitch will present …

You Might Also Like

Read more about the article WORLDCARE CLINICAL COMMENCES PHASE III CLINICAL TRIAL FOR TREATMENT OF SOFT TISSUE SARCOMA

WORLDCARE CLINICAL COMMENCES PHASE III CLINICAL TRIAL FOR TREATMENT OF SOFT TISSUE SARCOMA

March 28, 2017
Read more about the article WORLDCARE CLINICAL COMMENCES DXA AND MRI SERVICES ON NON-ALCOHOLIC FATTY LIVER DISEASE STUDY

WORLDCARE CLINICAL COMMENCES DXA AND MRI SERVICES ON NON-ALCOHOLIC FATTY LIVER DISEASE STUDY

June 15, 2020
Read more about the article WORLDCARE CLINICAL ADVANCES RESEARCH IN BETA THALASSEMIA CLINICAL TRIALS

WORLDCARE CLINICAL ADVANCES RESEARCH IN BETA THALASSEMIA CLINICAL TRIALS

April 19, 2019

Recent Posts

  • WorldCare Clinical, a leader in medical imaging and event adjudication solutions for clinical trials announces a series of leadership appointments
  • WORLDCARE CLINICAL ACQUIRES LEADING OPHTHALMOLOGY IMAGING CORE LAB
  • WORLDCARE CLINICAL COMMENCES INDEPENDENT REVIEW OF LARGE PHASE III MELANOMA TRIAL
  • WORLDCARE CLINICAL COMMENCES DXA AND MRI SERVICES ON NON-ALCOHOLIC FATTY LIVER DISEASE STUDY
  • WORLDCARE CLINICAL SAFETY COMMITTEES PROVIDE SOLUTION FOR COVID-19 VACCINE CLINICAL TRIALS

Recent Comments

  • A WordPress Commenter on OUTSOURCING IN CLINICAL TRIALS – WEST COAST
logo

About Us

  • About us
  • Leadership
  • Careers
  • News
  • Contact Us

Quick Links

  • Privacy Policy
  • Terms of use
  • WorldPRO

Contact Us

Phone: +1.877.374.3207

Copyright © 2023 - WORLDCARE CLINICAL - All Rights Reserved.

Jeff Schneebaum

Director of Operations, Ophthalmology

Jeff oversees the operations of the ophthalmic team at WorldCare Clinical. Jeff has served as Director of Operations at Digital Angiography Reading Center (DARC) for more than 13 years, helping to build the first all-digital ophthalmic reading center for clinical trials. Jeff has more than 20 years of experience working at Fortune 100 companies such as Credit Suisse First Boston and Colgate Palmolive. Jeff joined WCC in 2021 with the combination of DARC and WCC.

Jason Slakter, M.D.

Medical Director

Dr. Slakter is an internationally recognized retinal disease specialist with over 30 years of experience in clinical practice. He created the Digital Angiography Reading Center (DARC), which is one of the largest centers for image evaluation for clinical trials of posterior segment disease with over 1,600 certified clinical sites in over 70 countries worldwide, serving as a key resource for industry-sponsored studies of new treatments for retinal disorders. Dr. Slakter is also a Clinical Professor of Ophthalmology at NYU School of Medicine and has published more than 100 papers and book chapters. Dr. Slakter serves as the Chief Executive Officer of Orphion Therapeutics, Inc., a gene therapy company focused on developing new treatments to meet unmet needs for rare genetic diseases. Dr. Slakter is WCC’s Medical Director for Ophthalmology and has worked with WCC since the combination of DARC and WCC in 2021.

Rona Osmani

Vice President, Quality Assurance and Regulatory Affairs

Rona Osmani is WorldCare Clinical’s Vice President of Quality Assurance and Regulatory Affairs. Ms. Osmani has over ten years of experience in GxP as a Certified Clinical Research Professional. As a member of the company’s executive team, Ms. Osmani directs corporate quality and compliance initiatives to lead a quality governance structure that is six sigma.  Previously in her career, Ms. Osmani held quality assurance positions at other imaging CROs. Ms. Osmani earned a B.A. in Public Health (epidemiology) in 2006 from UC Berkeley with distinctions as an Alumni Achievement Award Scholar.   

Matt Heggem

Vice President, Program Management

Matt Heggem oversees the progress and performance of key programs at WCC. He has over 17 years of experience supporting clinical trial programs in the imaging space across various therapeutic areas including Musculoskeletal, Immunology, Neurology, Cardiology, Orthopedics and Oncology. Before joining WCC, Matt held various leadership roles at Synarc and BioClinica, including most recent positions of Managing Director of Global Services and Director of Program & Project Management. To compliment his extensive program management experience, Matt has an MBA with a specialization in Project Management and holds PMP and PgMP certifications from the Project Management Institute.

Richard Walovitch, Ph. D.

Chief Scientific Officer

Dr. Walovitch is Chief Scientific Officer of WCC, which he joined as Chief Medical Officer in January 2009. Prior to joining WCC, he served as the Senior Vice President of clinical research at Acusphere, Inc., Vice President of Preclinical and Clinical Research at Epix Medical, and held various positions as Research Pharmacologist and Project Clinician in the Imaging Agent Group at the DuPont Merck Pharmaceutical Company. He completed his postdoctoral fellowship at the National Institute on Drug Abuse’s Addiction Research Center in the Neurochemistry section. Dr. Walovitch has a Doctorate in Pharmacology from the University of Illinois Medical Center and a Bachelor’s degree in biology from the University of Illinois. He is an author of more than 100 peer-reviewed publications, mostly in the field of medical imaging.

Aaron Timm

Chief Executive Officer

Aaron Timm is CEO of WorldCare Clinical. Aaron joined WCC as CEO in November 2014 and has led the company’s successful growth and global expansion. Prior to joining WCC, he served as Chief Executive Officer of Synarc, an imaging CRO, from 2010 to 2014. Aaron joined Synarc as General Counsel in 2005. Earlier in his career, he worked as General Counsel of Vitria Technology, a publicly-traded software company. Aaron began his career practicing corporate law with Orrick, Herrington, & Sutcliffe LLP in San Francisco. He graduated summa cum laude from Georgetown University and with honors from Harvard Law School.